Rezolute, Inc. current report, 31 October 2016

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by AntriBio, Inc. (not Rezolute, Inc.) on November 4, 2016, covering events that occurred on October 31, 2016. The filing details the entry into material definitive agreements regarding executive compensation and the adoption of a new equity incentive plan.

Key Financial Metrics and Agreements

The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to equity compensation:

  • Stock Option Plan: The Board adopted the 2016 Non-Qualified Stock Option Plan, authorizing the issuance of up to 35,000,000 shares of Common Stock.
  • Exercise Price: Options granted under the plan have an exercise price of $1.20 per share.
  • Term: Options are exercisable until October 31, 2026 (10-year term).
  • Initial Grants:
    • Nevan Elam (CEO/Chairman): 9,500,000 shares
    • Hoyoung Huh (Founder/SAB Chair): 8,500,000 shares
    • Sankaram Mantripragada (CSO): 5,000,000 shares
    • Morgan Fields (CAO): 1,000,000 shares
    • David Welch (Director): 750,000 shares
    • Barry Sherman (Director): 300,000 shares
  • Other Grants: An additional 3,160,000 shares were issued to other officers, key employees, and consultants.

Material Changes and Agreements

Amended Employment Agreement: The Company entered into a First Amended and Restated Employment Agreement with Founder Hoyoung Huh. The primary change is the removal of Transaction Related Bonuses from his original 2015 agreement.

Performance Vesting Conditions: Specific vesting conditions apply to the Chief Scientific Officer's grant:

  • 1.0 million shares vest upon FDA approval of an IND for AB101 and release of adequate clinical material.
  • 2.0 million shares vest upon requesting a pre-IND meeting for a new pipeline candidate.
  • 2.0 million shares vest upon requesting a pre-IND meeting for an additional pipeline candidate.

Outlook, Risks, and Management Commentary

The filing indicates a strategic focus on aligning executive interests with long-term clinical milestones, specifically FDA interactions (IND approvals and pre-IND meetings). The removal of transaction-related bonuses from the Founder's agreement suggests a shift away from immediate transactional incentives toward long-term operational and clinical goals. No specific financial guidance or liquidity risks are disclosed in this report.

Investor Verification Checklist

  • Verify the total dilution impact of the 35,000,000 share pool and the specific grants made on October 31, 2016.
  • Confirm the current status of the AB101 IND application and clinical material availability to assess vesting triggers for the CSO.
  • Review the full text of Exhibit 10.1 to understand the complete terms of the amended employment agreement with Dr. Huh.
  • Check subsequent filings for updates on the pre-IND meetings required to unlock the remaining CSO option grants.